CHARMING SHOPPES (NASDAQ:CHRS)
Industry: Services

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Current Quote*
Last: $13.590
Change: -0.160
Book: $2.000
Volume: 55,353

As Of: 11/26 17:43 PST ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol CHRS

  • No BuyIns.Net Alerts Available for CHRS

Graphs for CHRS


3 Month Graph


6 Month Graph


1 Year Graph